Immune checkpoints and immunotherapy for colorectal cancer

作     者：Preet Paul Singh Piyush K.Sharma Gayathri Krishnan A.Craig Lockhart 

作者机构：Division of OncologyWashington University School of MedicineSt.LouisMOUSA Department of SurgeryWashington University School of MedicineSt.LouisMOUSA 

出 版 物：《Gastroenterology Report》 (胃肠病学报道（英文）)

年 卷 期：2015年第3卷第4期

页      码：289-297,I0001页

摘      要：Colorectal cancer(CRC)remains one of the major causes of death worldwide,despite steady improvement in early detection and overall survival over the past *** treatment paradigms,with chemotherapy and biologics,appear to have reached their maximum ***,especially with checkpoint inhibitors,has shown considerable clinical benefit in various cancers,including mismatch-repair-deficient *** has led to the planning and initiation of several clinical trials evaluating novel immunotherapy agents—as single agents,combinations and in conjunction with chemotherapy—in patients with *** article reviews biological and preclinical data for checkpoint inhibitors and discusses various immunotherapy trials in CRC,as well as current efforts in CRC immunotherapy.

主 题 词：immunotherapy colorectal cancer checkpoint inhibition/blockade programmed death 1(PD-1) cytotoxic Tlymphocyte-associated antigen 4(CTLA-4) vaccine pembrolizumab 

学科分类：1002[医学-临床医学类] 100214[100214] 10[医学] 

核心收录：

D　O　I：10.1093/gastro/gov053

馆 藏 号：203325517...